Top Page
Nutritional Growth Solutions Ltd.
(Sydney:NGS)
Nutritional Growth Solutions Ltd. (NGS) vs. iShares MSCI Australia ETF (EWA)
Nutritional Growth Solutions Ltd. Business Overview & Revenue Model
Nutritional Growth Solutions Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.10M | 2.48M | 3.06M | 2.95M | 3.04M | 1.87M |
| Gross Profit | 561.00K | 811.00K | 842.00K | 1.44M | 1.36M | 920.00K |
| EBITDA | -2.28M | -2.45M | -3.01M | -4.32M | -4.71M | -2.24M |
| Net Income | -2.44M | -2.54M | -2.89M | -4.25M | -4.78M | -4.36M |
Balance Sheet | ||||||
| Total Assets | 589.00K | 709.00K | 936.00K | 3.03M | 3.44M | 4.00M |
| Cash, Cash Equivalents and Short-Term Investments | 110.00K | 31.00K | 172.00K | 1.52M | 3.00M | 3.55M |
| Total Debt | 1.04M | 162.00K | 362.00K | 37.00K | 73.00K | 98.93K |
| Total Liabilities | 2.35M | 1.37M | 1.11M | 954.00K | 626.97K | 685.60K |
| Stockholders Equity | -1.76M | -658.00K | -177.00K | 2.08M | 2.81M | 3.31M |
Cash Flow | ||||||
| Free Cash Flow | -2.08M | -1.93M | -2.35M | -6.98M | -3.74M | -1.81M |
| Operating Cash Flow | -2.08M | -1.93M | -2.35M | -6.97M | -3.69M | -1.75M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -4.00K | -63.06K | -58.28K |
| Financing Cash Flow | 2.07M | 1.78M | 998.00K | 2.21M | 3.42M | 5.69M |
Nutritional Growth Solutions Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | AU$30.53M | 36.09 | ― | ― | 6.76% | ― | |
43 Neutral | AU$7.33M | -0.67 | ― | ― | -21.84% | 79.99% | |
41 Neutral | AU$6.55M | -2.02 | -60.84% | ― | -18.70% | 20.83% | |
38 Underperform | AU$21.00M | -5.17 | -29.43% | ― | 102.21% | 69.47% | |
38 Underperform | AU$2.33M | -0.49 | -115.03% | ― | 24.70% | -312.00% |
Nutritional Growth Solutions Ltd. Corporate Events
Nutritional Growth Solutions Ltd. has issued 100 million fully paid ordinary shares at $0.02 each to professional and sophisticated investors, following shareholder approval at a general meeting on 23 December 2025. The company confirmed the shares were issued without a prospectus under applicable Corporations Act provisions, stated that it remains compliant with its continuous disclosure and reporting obligations, and affirmed there is no excluded information, signalling a routine capital-raising step designed to support its operations while maintaining regulatory transparency for investors.
Nutritional Growth Solutions Ltd has applied to the ASX for quotation of 100 million new fully paid ordinary shares, with an issue date of 24 December 2025, under an Appendix 2A application following a previously announced Appendix 3B transaction. The substantial share issuance is expected to expand the company’s equity base and may support future capital needs, potentially influencing its market liquidity, ownership structure and capacity to fund strategic initiatives.
Nutritional Growth Solutions Ltd has announced the resignation of director Stephen Turner, who ceased to be a board member on 24 December 2025. In his final director’s interest notice to the ASX, the company disclosed that Turner retains significant holdings in the company, including ordinary shares and options, indicating that while he is stepping down from a governance role he remains financially exposed to the company’s performance, a point of note for investors monitoring board changes and ownership structure.
Nutritional Growth Solutions has announced that CEO and Managing Director Stephen J. Turner will step down from his role, effective 30 January 2026, under a mutual agreement with the board. Turner will remain with the company until his departure date to ensure an orderly handover of information, systems and operational responsibilities, with all his remuneration and entitlements settled in full. Non-executive director Andrew Grover, an experienced executive and investor known for business turnarounds and growth, will assume the role of interim CEO without additional remuneration while the board searches for a permanent chief executive, signaling a leadership transition aimed at maintaining operational continuity and potentially sharpening the company’s strategic and commercial focus.
Nutritional Growth Solutions has issued 12,965,673 fully paid ordinary shares at $0.021760 each to Dicofarm S.p.A., following shareholder approval at a general meeting on 23 December 2025. The new shares were issued without a disclosure document under the Corporations Act’s fundraising provisions, with the company confirming it is compliant with financial reporting and continuous disclosure obligations and stating there is no excluded information, signaling routine capital management while maintaining regulatory transparency for investors.
Nutritional Growth Solutions Ltd. has applied to the ASX for quotation of 12,965,673 new fully paid ordinary shares, scheduled to be issued on 24 December 2025. The new securities, which follow a previously announced transaction, will expand the company’s quoted share capital and may influence its market liquidity and investor base as it continues executing its capital and growth plans.
Nutritional Growth Solutions Ltd has announced a change in director Stephen Turner’s interests in the company’s securities, following shareholder approval at an extraordinary general meeting held on 23 December 2025. Turner acquired 2,107,692 new ordinary shares at $0.03 per share and transferred 1,250,000 existing shares to Citicorp Nominees Pty Limited as custodian for administrative purposes, a move that did not alter his beneficial ownership. After the change, Turner holds a combination of direct and indirect interests in ordinary shares and previously issued options, reflecting an increased equity stake that further aligns his interests with those of shareholders.
Nutritional Growth Solutions Ltd. has issued 5,959,775 fully paid ordinary shares without a prospectus under Australian disclosure rules, and has confirmed its ongoing compliance with key financial reporting and continuous disclosure obligations under the Corporations Act. The cleansing notice indicates there is no excluded information withheld from the market, supporting transparency for investors as the company adjusts its capital structure and potentially broadens its shareholder base.
Nutritional Growth Solutions Ltd has notified the ASX that it will issue 25 million unquoted options exercisable at A$0.025 and expiring on 23 December 2028, with the issue scheduled for 29 December 2025. The options form part of a previously announced transaction and will not be quoted on the ASX, indicating a capital structure move that may affect existing holders through potential future dilution while providing additional incentive or funding flexibility for the company’s stakeholders involved in that transaction.
Nutritional Growth Solutions Ltd. has announced that all resolutions put to shareholders at its 23 December 2025 General Meeting were passed by poll. The approvals cover ratification of prior share issues, the issuance of shares to key individuals and partners, the establishment of an incentive plan, and the issuance of securities tied to a recent placement and lead manager options, collectively reinforcing the company’s capital structure and incentives framework as it pursues growth in the pediatric nutritional supplements market.
Nutritional Growth Solutions Ltd. has secured an interim loan facility from a company director to provide short-term working capital. This facility, amounting to A$250,000 with A$80,000 already drawn, is interest-free and unsecured, intended to bridge the gap until a proposed A$2.0 million placement is approved and completed. This financial maneuver is crucial for maintaining operations and improving the company’s cash position, pending shareholder approval of the placement.
Nutritional Growth Solutions Ltd has announced the appointment of Mr. Manik Pujara as a director, effective from November 17, 2025. Mr. Pujara holds a significant interest in the company through Trinetra Holdings Pty Ltd, which owns 5,000,000 fully paid ordinary shares. This appointment may influence the company’s strategic direction and potentially impact its market positioning, given Mr. Pujara’s vested interest in the company’s growth.
Nutritional Growth Solutions Ltd announced the appointment of Mr. Andrew Grover as a director, effective November 17, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team, potentially impacting its market positioning and stakeholder relations positively.
Nutritional Growth Solutions Ltd. has announced the appointment of Andrew Grover as a Non-Executive Director and Manik Pujara as an Executive Director, effective November 17, 2025. Grover, with over 25 years of experience in various industries, is expected to drive growth and operational excellence, while Pujara’s appointment reflects confidence in his leadership to support the company’s strategic growth and long-term objectives. These appointments are aimed at enhancing the company’s governance and operational strategies, positioning NGS for profitability and sustainable value creation in the nutritional supplements market.
Nutritional Growth Solutions Ltd has announced a proposed issue of 28,214,600 ordinary fully paid securities, scheduled for December 24, 2025. This move is part of a placement or other type of issue, which could potentially enhance the company’s capital base and support its strategic initiatives, thereby impacting its market position and offering potential benefits to stakeholders.
Nutritional Growth Solutions Ltd. announced the dispatch of documents related to its upcoming General Meeting to shareholders, including a letter, notice of meeting, and proxy form. The meeting will be held virtually, allowing shareholders to participate online. This announcement underscores the company’s commitment to engaging with its stakeholders and maintaining transparency in its operations, which is crucial for its market positioning and shareholder relations.
Nutritional Growth Solutions Ltd announced a proposed issue of securities, including 25 million unlisted options and 100 million ordinary fully paid shares, set to be issued on December 18, 2025. This strategic move is expected to bolster the company’s financial position and enhance its market presence, potentially impacting stakeholders positively by providing additional capital for growth initiatives.
Nutritional Growth Solutions Limited has secured commitments to raise A$2 million through a share placement at A$0.02 per share, pending shareholder approval. The funds will be used for sales and marketing, inventory build, general expenses, and growth opportunities, positioning the company for expansion in the children’s nutritional supplements market.
Nutritional Growth Solutions Ltd. reported a 13% increase in revenue for Q3 FY25, reaching US$486k, driven by improved inventory and retail momentum. The company expanded its retail presence with Happy Tummies® now available in approximately 5,500 CVS stores and renewed Walmart placements, which now include three KidzProtein® SKUs. Despite elevated administrative costs, disciplined cost management led to reduced operating expenses. The company completed a share placement raising AU$760k to support its US retail rollout and maintain working capital, with cash reserves at US$169k at the quarter’s end. CEO Stephen Turner expressed optimism about the company’s progress towards profitability and commitment to long-term shareholder value.
Nutritional Growth Solutions Ltd (ASX: NGS) has requested a trading halt on its securities pending an announcement regarding a capital raising. The halt is expected to remain until either the start of normal trading on November 3, 2025, or until the announcement is released. This move is likely aimed at strengthening the company’s financial position to support its growth strategy in the expanding children’s nutritional supplements market.
Nutritional Growth Solutions Ltd announced the cessation of 2,000,000 securities due to the expiry of options without exercise or conversion as of October 23, 2025. This development may impact the company’s capital structure and could have implications for its market positioning and stakeholder interests.